Like CDK4/6i, BRAF and MEK inhibitors (BRAFi + MEKi), which inhibit the MAPK/ERK pathway, were originally developed to block tumor cell proliferation and survival, but were subsequently discovered to augment anti-tumor immunity23–28. This evidence concerns the gene BRAF and neoplasm.